Soluble fas ligand and soluble fas in hemophagocytic lymphohistiocytosis

Shouichi Ohga, Hidetoshi Takada, Yumi Mizuno, Keiko Honda, Akihiko Nomura, Toshiro Hara

Research output: Contribution to journalArticle

Abstract

Parpose: To further understand the hypercytokinemic state in hemophagocytic lymphohistiocytosis (HLH), serum levels of soluble Fas ligand (sFasL) and soluble Fas (sFas) were measured in HLH-patients, and compared with the levels of tumour necrosis factor (TNF)- α, Interferon (IFN)- γ, and soluble imerleukin-2 receptor (sIL-2R), along with clinical and laboratory findings. Patients and Methods: Serum was obtained from 11 patients who fulfilled the diagnostic criteria of HLH (Henter 1991, Imashuku 1997) Concentrations of sFasL and sFas were measured by ELISA kits (sFasL; MBL, Nagoya, sFas; Oriental Koubo, Osaka). Results: Serum sFasL levels were higher in HLH-patients (mean 4703, max 16772 pg/ml) than in patients with Epstein-Barr virus infection (mean 1194 pg/ml) or in healthy controls (<100 pg/ml). On the other hand, serum sFas levels did not increase in HLH-patients. The sFasL levels positively correlated with ALT levels (rS=0.709, p<0.05), but not with the levels of TNF- α, IFN- γ, SIL-2R, AST, LDH, ferritin, CRP, total cholesterol, and triglyceride The CD4/CD8 ratio and numbers of CD3+HLA-DR+ cells did not also correlate with serum sFasL levels Conclusions: Serum increase of sFasL was reported in T-LGL leukemia, NK cell lymphoma and rheumatic diseases Our results suggest that the circulating levels of sFasL well reflect the liver damage in HLH irrespective of Th1 type hypercytokinemia, although it is not known whether sFasL induces or inhibits the Fas-mediated tissue injury in lymohohistiocytic activation.

Original languageEnglish
Number of pages1
JournalMedical and Pediatric Oncology
Volume32
Issue number3
Publication statusPublished - Dec 1 1999

Fingerprint

Hemophagocytic Lymphohistiocytosis
Fas Ligand Protein
Serum
Interferons
Tumor Necrosis Factor-alpha
Large Granular Lymphocytic Leukemia
CD4-CD8 Ratio
Epstein-Barr Virus Infections
HLA-DR Antigens
Ferritins
Rheumatic Diseases
Natural Killer Cells
Lymphoma
Triglycerides
Enzyme-Linked Immunosorbent Assay
Cholesterol

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

Ohga, S., Takada, H., Mizuno, Y., Honda, K., Nomura, A., & Hara, T. (1999). Soluble fas ligand and soluble fas in hemophagocytic lymphohistiocytosis. Medical and Pediatric Oncology, 32(3).

Soluble fas ligand and soluble fas in hemophagocytic lymphohistiocytosis. / Ohga, Shouichi; Takada, Hidetoshi; Mizuno, Yumi; Honda, Keiko; Nomura, Akihiko; Hara, Toshiro.

In: Medical and Pediatric Oncology, Vol. 32, No. 3, 01.12.1999.

Research output: Contribution to journalArticle

Ohga, S, Takada, H, Mizuno, Y, Honda, K, Nomura, A & Hara, T 1999, 'Soluble fas ligand and soluble fas in hemophagocytic lymphohistiocytosis', Medical and Pediatric Oncology, vol. 32, no. 3.
Ohga, Shouichi ; Takada, Hidetoshi ; Mizuno, Yumi ; Honda, Keiko ; Nomura, Akihiko ; Hara, Toshiro. / Soluble fas ligand and soluble fas in hemophagocytic lymphohistiocytosis. In: Medical and Pediatric Oncology. 1999 ; Vol. 32, No. 3.
@article{fd22f27366bf4b008e7b465825aa676a,
title = "Soluble fas ligand and soluble fas in hemophagocytic lymphohistiocytosis",
abstract = "Parpose: To further understand the hypercytokinemic state in hemophagocytic lymphohistiocytosis (HLH), serum levels of soluble Fas ligand (sFasL) and soluble Fas (sFas) were measured in HLH-patients, and compared with the levels of tumour necrosis factor (TNF)- α, Interferon (IFN)- γ, and soluble imerleukin-2 receptor (sIL-2R), along with clinical and laboratory findings. Patients and Methods: Serum was obtained from 11 patients who fulfilled the diagnostic criteria of HLH (Henter 1991, Imashuku 1997) Concentrations of sFasL and sFas were measured by ELISA kits (sFasL; MBL, Nagoya, sFas; Oriental Koubo, Osaka). Results: Serum sFasL levels were higher in HLH-patients (mean 4703, max 16772 pg/ml) than in patients with Epstein-Barr virus infection (mean 1194 pg/ml) or in healthy controls (<100 pg/ml). On the other hand, serum sFas levels did not increase in HLH-patients. The sFasL levels positively correlated with ALT levels (rS=0.709, p<0.05), but not with the levels of TNF- α, IFN- γ, SIL-2R, AST, LDH, ferritin, CRP, total cholesterol, and triglyceride The CD4/CD8 ratio and numbers of CD3+HLA-DR+ cells did not also correlate with serum sFasL levels Conclusions: Serum increase of sFasL was reported in T-LGL leukemia, NK cell lymphoma and rheumatic diseases Our results suggest that the circulating levels of sFasL well reflect the liver damage in HLH irrespective of Th1 type hypercytokinemia, although it is not known whether sFasL induces or inhibits the Fas-mediated tissue injury in lymohohistiocytic activation.",
author = "Shouichi Ohga and Hidetoshi Takada and Yumi Mizuno and Keiko Honda and Akihiko Nomura and Toshiro Hara",
year = "1999",
month = "12",
day = "1",
language = "English",
volume = "32",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Soluble fas ligand and soluble fas in hemophagocytic lymphohistiocytosis

AU - Ohga, Shouichi

AU - Takada, Hidetoshi

AU - Mizuno, Yumi

AU - Honda, Keiko

AU - Nomura, Akihiko

AU - Hara, Toshiro

PY - 1999/12/1

Y1 - 1999/12/1

N2 - Parpose: To further understand the hypercytokinemic state in hemophagocytic lymphohistiocytosis (HLH), serum levels of soluble Fas ligand (sFasL) and soluble Fas (sFas) were measured in HLH-patients, and compared with the levels of tumour necrosis factor (TNF)- α, Interferon (IFN)- γ, and soluble imerleukin-2 receptor (sIL-2R), along with clinical and laboratory findings. Patients and Methods: Serum was obtained from 11 patients who fulfilled the diagnostic criteria of HLH (Henter 1991, Imashuku 1997) Concentrations of sFasL and sFas were measured by ELISA kits (sFasL; MBL, Nagoya, sFas; Oriental Koubo, Osaka). Results: Serum sFasL levels were higher in HLH-patients (mean 4703, max 16772 pg/ml) than in patients with Epstein-Barr virus infection (mean 1194 pg/ml) or in healthy controls (<100 pg/ml). On the other hand, serum sFas levels did not increase in HLH-patients. The sFasL levels positively correlated with ALT levels (rS=0.709, p<0.05), but not with the levels of TNF- α, IFN- γ, SIL-2R, AST, LDH, ferritin, CRP, total cholesterol, and triglyceride The CD4/CD8 ratio and numbers of CD3+HLA-DR+ cells did not also correlate with serum sFasL levels Conclusions: Serum increase of sFasL was reported in T-LGL leukemia, NK cell lymphoma and rheumatic diseases Our results suggest that the circulating levels of sFasL well reflect the liver damage in HLH irrespective of Th1 type hypercytokinemia, although it is not known whether sFasL induces or inhibits the Fas-mediated tissue injury in lymohohistiocytic activation.

AB - Parpose: To further understand the hypercytokinemic state in hemophagocytic lymphohistiocytosis (HLH), serum levels of soluble Fas ligand (sFasL) and soluble Fas (sFas) were measured in HLH-patients, and compared with the levels of tumour necrosis factor (TNF)- α, Interferon (IFN)- γ, and soluble imerleukin-2 receptor (sIL-2R), along with clinical and laboratory findings. Patients and Methods: Serum was obtained from 11 patients who fulfilled the diagnostic criteria of HLH (Henter 1991, Imashuku 1997) Concentrations of sFasL and sFas were measured by ELISA kits (sFasL; MBL, Nagoya, sFas; Oriental Koubo, Osaka). Results: Serum sFasL levels were higher in HLH-patients (mean 4703, max 16772 pg/ml) than in patients with Epstein-Barr virus infection (mean 1194 pg/ml) or in healthy controls (<100 pg/ml). On the other hand, serum sFas levels did not increase in HLH-patients. The sFasL levels positively correlated with ALT levels (rS=0.709, p<0.05), but not with the levels of TNF- α, IFN- γ, SIL-2R, AST, LDH, ferritin, CRP, total cholesterol, and triglyceride The CD4/CD8 ratio and numbers of CD3+HLA-DR+ cells did not also correlate with serum sFasL levels Conclusions: Serum increase of sFasL was reported in T-LGL leukemia, NK cell lymphoma and rheumatic diseases Our results suggest that the circulating levels of sFasL well reflect the liver damage in HLH irrespective of Th1 type hypercytokinemia, although it is not known whether sFasL induces or inhibits the Fas-mediated tissue injury in lymohohistiocytic activation.

UR - http://www.scopus.com/inward/record.url?scp=33748072424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748072424&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748072424

VL - 32

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 3

ER -